News Roche hails 4 year NICE access deal for Gazyvaro NICE has agreed a deal with Roche on its new follicular lymphoma treatment Gazyvaro, giving the dru
News FDA cites 'significant concerns' with ADC lymphoma trial ADC Therapeutics' chances of upgrading its accelerated approval for DLBCL therapy Zynlonta to a full approval have taken a knock.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
